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Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder in which the 
loss of upper and lower motor neurons produces progressive weakness and eventually death. In 
the decades since the approval of riluzole, the only FDA approved medication to moderately 
slow progression of ALS, no new therapeutics have arisen to alter the course of the disease. This 
is partly due to our incomplete understanding of the complex pathogenesis of motor neuron 
degeneration. Stem cells have emerged as an attractive option in treating ALS since they come 
armed with equally complex cellular machinery and may modulate the local microenvironment 
in many ways to rescue diseased motor neurons. While various stem cell types are being 
evaluated in preclinical and early clinical applications, here we review the preclinical strategies 
and advances supporting the recent clinical translation of neural progenitor cell therapy for ALS. 
Specifically, we focus on the use of spinal cord neural progenitor cells and the pipeline starting 
from preclinical studies to the designs of the Phase I and IIa clinical trials involving direct 
intraspinal transplantation in humans.
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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the 
selective and progressive degeneration of upper and lower motor neurons, with an estimated cost 
to society ranging from $256 million to $433 million in the United States alone.1 ALS manifests 
as an insidious, inexorable decline in motor function, with progressively compromised strength, 
coordination, gait, and respiratory function, leading to death within an average of 3-5 years from 
diagnosis.2 Approximately 15% of cases are associated with germline mutations in a number of 
genes, including Cu2+/Zn2+ superoxide dismutase (SOD1), transactive response DNA-binding 
protein 43 (TDP43), fused in sarcoma (FUS), and the more recently described hexanucleotide 
repeat expansions in the chromosome 9 open reading frame 72 (c9orf72).3 The vast majority of 
ALS cases, however, are sporadic, and the underlying pathophysiology remains unclear.  
Many hypotheses exist to explain motor neuron death in ALS, including excitotoxicity,4-8 
loss of neurotrophic factors,9-11 inflammatory signaling,12 mitochondrial pathology,13, 14 and 
endoplasmic reticulum dysfunction and protein misfolding,15 among others.16 This complexity 
has stood in the way of successful development of mechanism-based pharmaceutical treatments, 
and riluzole, a drug that extends survival by mere months, remains the only United States Food 
& Drug Administration (FDA)-approved therapy for ALS.17 Disappointingly, a number of trials 
targeting some of the above-mentioned pathways have failed in large-scale clinical trials.18-36 
Given the multifaceted nature of ALS, stem cell-based therapy has recently become an 
attractive option. Initially proposed as a means for motor neuron replacement, stem cells may 
actually provide a number of benefits by modulating the local microenvironment to facilitate 
native motor neuron survival. Stem cells elaborate neurotrophic factors such as glial-derived 
neurotrophic factors (GDNF), brain-derived neurotrophic factor (BDNF), vascular endothelial 
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growth factor (VEGF), and insulin-like growth factor-I (IGF-I).37, 38 Certain stem cells can also 
differentiate into astrocytes and increase efficiency of glutamate re-uptake, a process that is 
disrupted in ALS.39 Furthermore, stem cells that form neuronal cells may form synapses onto 
native motor neurons and provide trophic and/or contact-mediated support.40   
In translating a stem cell-based approach from bench top studies to clinical trials, a 
number of criteria must be achieved. First, the appropriate type of stem cell must be identified 
and be obtainable in numbers that can be used therapeutically. Second, the means of cell delivery 
must be carefully considered, balancing the risks of invasive procedures with the need to deliver 
sufficient cells to specific areas within the nervous system. Here, we review the strategy of 
modulating the motor neuron microenvironment using cellular-based techniques and briefly 
introduce the current options being developed as cellular therapies. We then emphasize the 
preclinical data supporting our own journey toward a clinical trial using neural progenitor cells 
(NPCs) in ALS, and finally describe the results of our Phase I trial, outline the Phase IIa trial 
which has recently concluded, and offer perspective on the future of stem cell-based treatment 
for ALS. 
 
STEM CELLS: MODULATING THE LOCAL MICROENVIRONMENT 
The possibility of cellular replacement generated considerable enthusiasm for stem cell 
applications in neurodegenerative diseases, including ALS. Early data fueled this fervor, with 
studies in chicks showing the ability of stem cells to differentiate into motor neurons and 
reinnervate muscle.41 This was then applied to rodent models of ALS bearing the first described 
familial ALS mutation (SOD1G93A) and exhibiting a phenotype of progressive motor neuron loss 
and weakness42, 43; however, it quickly became apparent that hurdles for motor neuron 
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replacement included not only introduction of stem cells into the spinal cord without damage to 
surrounding neural tissue, but also efficient differentiation into motor neurons, integration with 
local circuitry, growth of new axons in the mature central nervous system (CNS), proper axonal 
guidance to correct musculature, formation of mature neuromuscular junctions, and sufficient 
pruning for functional activity.44 At this time, these hurdles cannot be overcome with our current 
technologies.  
For true reconstruction of the motor system, biotechnology must advance to a point 
where implanted stem cells can receive new synaptic contacts as well as sprout new axons, 
typically impermissible in the CNS. These new axons must then be coaxed to enter ventral roots 
and follow a “bread crumb trail” of neurotrophic factors to create de novo neuromuscular 
junctions. While early work to achieve this has been attempted,45, 46 the difficulties in translating 
these strategies to clinical practice have been prohibitive, especially considering the short 
survival window for ALS patients. Some strategies to address or bypass some of these barriers 
capitalize on intact transport functions of the nervous system; for example, targeting skeletal 
muscle allows neurotrophic factors, nucleic acids, or viral vectors to be brought to the 
appropriate motor neurons in the ventral horn via retrograde transport.47-51 Similarly, intracranial 
injections of stem cells have been attempted to widely affect the motor system in an anterograde 
fashion.52-54 These multimodality and multisite strategies, combined with novel biomaterials that 
carry various biologics and new techniques for delivery (e.g. ever miniaturized robotics or 
advanced image-guided intervention) could make motor neuron replacement a real strategy in the 
future. 
For now, despite the selective vulnerability of alpha motor neurons in ALS, evidence has 
accumulated to suggest that ALS is not solely a disease of motor neurons, but rather one in 
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which the local “neighborhood” contributes to motor neuron demise.55-57 Elegant experiments 
performed in chimeric mutant SOD1 mice showed that motor neuron death was linked to 
surrounding non-neuronal genotype rather than intrinsic properties of the neurons themselves: 
normal motor neurons surrounded by mutant SOD1-expressing non-neuronal cells displayed 
characteristics of degeneration akin to that seen in ALS, whereas mutant SOD1-expressing motor 
neurons surrounded by wild-type non-neuronal cells were protected from cell death.58 Again, the 
exact mechanisms of this are unclear, but it is now fairly well-established that motor neuron 
interaction with surrounding neurons, astrocytes, vasculature, skeletal muscle, microglia, and 
other immune cells contribute to motor neuron death.6, 59-62 Stem cells enter this scene armed 
with the full armamentarium of cellular processes (neurotransmitter uptake, synapse formation, 
inflammatory signaling, neurotrophic factor signaling, etc.) that can ameliorate toxic 
environments in a multifactorial fashion, a process difficult to achieve by small molecule therapy 
alone. Indeed, as pharmacologics advance, small molecule therapies may work synergistically 
with stem cells, and the combination could form the basis for future paradigms in clinical trial 
design. 
There are many options to consider when developing a stem cell-based cellular therapy. 
This includes selection of the optimal stem cell type, and recent studies have focused on the 
potential utility of embryonic stem cells, olfactory ensheathing cells,63-66 peripheral blood stem 
cells,53, 67-73 adipose stem cells,74 bone marrow-derived mesenchymal stem cells,75-81 and NPCs.82 
Determination of the optimal therapeutic delivery paradigm is also pertinent, and approaches 
range from systemic mobilization or intravenous delivery to precise localized delivery strategies 
within the CNS. Recent progress detailing the preclinical development and early clinical 
translation of these varying therapeutic strategies are reviewed elsewhere,83-86 and these advances 
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collectively provide important insights into the potential safety, feasibility, and preliminary 
efficacy of the stem cell therapies currently being considered to treat ALS around the world; 
however, here we present our recent journey developing and translating a spinal cord NPC-based 
therapy for ALS.  
 
SPINAL CORD NPCs  
The Path Towards Clinical Testing 
NPCs are pluripotent cells that have undergone the initial stages of differentiation, such 
that the cell types that arise are limited to neuronal and glial lineages. Over the past decade, our 
recent preclinical validation and clinical translation efforts have focused on the utilization of 
NSI-566RSC, an established NPC cell line generated from donated fetal spinal cord tissue.38, 40, 87 
While mesenchymal stem cells obtained from bone marrow, peripheral blood, umbilical cord 
blood and adipose tissue can be expanded and transplanted autologously with less risk of 
rejection, these cells cannot recapitulate neuronal synapses that might be crucial for rescuing 
motor neurons. Also, NPCs obtained from embryonic tissue have been spared the possible 
disease-related environmental exposure and epigenetic changes seen by the patient. However, on 
the other side of the spectrum, part of the risk of using more primitive embryonic stem cells or 
even olfactory ensheathing cells is ongoing proliferation and formation of teratomatous 
tumors.88, 89 Thus, while a disadvantage of using a NPC line is the immunosuppression required, 
the benefit comes from the ability of “fresh” NPCs to generate CNS-relevant cell types, form 
synapses, and still possess a decreased “tumorigenic” profile.  
Initial preclinical studies assessing the therapeutic potential of the NSI-566RSC line in 
SOD1G93A rats showed that transplanted stem cells rescued motor neurons, improved motor 
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function, and prolonged lifespan.38, 40, 90, 91 These studies further supported a mechanism whereby 
the transplanted cells modulated the local microenvironment by forming synapses with host 
motor neurons and eliciting neurotrophic signaling that rescued motor neurons only in the area of 
stem cell injection.38, 40 Notably, studies targeting both lumbar and cervical spinal cord segments 
in SOD1G93A mice demonstrated that dual targeting conferred greater therapeutic benefit.87  
Further preclinical assessments along the pathway toward clinical translation included 
verification of the safety of intraspinal stem cell injection in a large animal. Intraspinal injection 
carries the greatest degree of risk for neurologic damage, thus limiting interventions to defined 
segments of the CNS. However, in contrast to intravascular or intrathecal administration, direct 
injection ensures localization of viable cells in the region of interest (here, the ventral horn of 
spinal cord). Thus, the potential for local growth factor production and synapse formation can be 
maximized, while at the same time bypassing the blood brain barrier. Studies performed by a 
team led by Dr. Nicholas Boulis at Emory University proved critical in validating this approach, 
as delivery of a payload of cells by direct injection was a daunting task considering that accurate 
needle placement must be made into the anterior horn without damaging the exquisitely sensitive 
surrounding structures of the spinal cord. Added to this is the fact that this microscopic target 
moves and pulsates in response to the patient’s variable heart rate and respirations. Thus, a 
specialized spinal cord injection device was devised (Figure 1).84 The device is anchored to the 
patient’s own bony anatomy and therefore grossly moves with the patient, enhancing safety if an 
adjustment of the operative table is needed or if the patient exhibits any intra-operative 
movement. A “gondola” affixed to this anchored frame carries a multi-axial “Z-drive”, allowing 
the surgeon to precisely angulate and space each injection. The injection needle design is based 
on pre-operative imaging with a stop such that when the hub is at the dorsal spinal cord surface, 
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the needle length (3-5 mm, based on distance to anterior horn as measured on pre-operative 
MRI) places the injection tip in the anterior horn. This injection needle is connected to flexible 
tubing, allowing the needle to “float” and move with the pulsations of the spinal cord without 
causing unnecessary trauma.  
Iterations of this device were designed for targeting the cervical or lumbar spinal cord 
segments and were then tested and optimized in the Gottingen minipig.92-94 These experiments 
showed that minipigs tolerated 5 or 10 unilateral injections (6 µL per injection) in cervical spinal 
cord. Most animals recovered motor and sensory function within 6 days of surgery and all 
recovered to preoperative baselines by postoperative day 14. Initial immunosuppression 
protocols using tacrolimus and methylprednisolone were also optimized in these experiments to 
maximize xenogeneic cell survival. These studies not only demonstrated that injected cells were 
accurately placed within the anterior horn of the spinal cord using the spinal delivery frame 
(Figure 1),84 but most importantly, that the animals recovered with robust limb motor function 
after their surgical procedures, providing confidence that such an approach could be successful in 
man.  
 
A Phase I Clinical Trial 
Preclinical evidence of NPC transplantation efficacy in the SOD1G93A rat along with 
demonstration of the feasibility and safety of spinal cord injection using the spinal injection 
device in the minipig supported approval from the FDA for the trial “A Phase l, Open-label, First in 
Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation 
for the Treatment of Amyotrophic Lateral Sclerosis” (NCT01348451). Given the novelty of this 
intervention, the trial utilized a “risk escalation” design in terms of subject disease severity, 
intervention target, and injection numbers (Table 1). Dr. Jonathan Glass at Emory University 
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coordinated a team of Neurologists and Neurosurgeons to test this novel approach.82 Group A 
included non-ambulatory patients who received 5 unilateral (n = 3 subjects) or 10 bilateral (n = 3 
subjects) injections in the lumbar spinal cord (L2-4), whereas Group B (n = 3 subjects) and C (n 
= 3 subjects) included ambulatory subjects who received 5 unilateral or 10 bilateral injections 
into the lumbar spinal cord, respectively. Group D (n = 3 subjects) included ambulatory patients 
who received 5 unilateral cervical spinal cord injections (C3-5). Notably, these cervical 
injections target the motor neurons innervating the diaphragm, thus offering a means to offer 
protection against the most common cause of death in ALS – respiratory failure. The 3 patients 
in group C then received 5 unilateral cervical spinal cord injections in addition to their lumbar 
injections and formed Group E. To ensure survival of the transplanted stem cells, patients 
received methylprednisolone and basiliximab at the time of surgery, and were maintained post-
operatively using another dose of basiliximab, a prednisone taper, and maintenance tacrolimus 
and mycophenolate mofetil. Further details of the clinical trial as well as the surgical 
implantation technique have been described elsewhere.84, 95-98 
To date, 7 deaths have been recorded among the patients enrolled in the Phase I trial; 6 
due to progression of the disease and one due to a previously undiagnosed congenital cardiac 
defect. Autopsy studies on postmortem spinal cord tissue from these subjects have provided 
exciting data to support the feasibility of surgical implantation of NPCs in ALS. First, in terms of 
safety, no tumor formation was evident in any subject. Second, histological assessments revealed 
nests of live cells representative of the transplanted NPCs in the regions targeted by the 
transplants, and male donor cells were evident in the female transplant recipients (Figure 2).99 
Moreover, every patient at autopsy demonstrated the persistence of donor-specific DNA in 
injected spinal cord when assayed for donor HLA genotype by qPCR (Figure 3).99 
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In the Phase I trial, while a number of adverse events (AEs) were observed, most were 
related to the immunosuppression regimen initiated to ensure engraftment of implanted stem 
cells82 and no AEs were related to the surgical procedure,97, 98 emphasizing the safety and 
tolerability of this cellular therapy and transplantation technique. Furthermore, clinical 
assessments including ALS functional rating scale-revised (ALSFRS-R), ALS quality of life 
(ALSQOL), forced vital capacity (FVC), hand-held dynamometry (HHD), and grip strength 
testing (GST) showed no acceleration of disease course. In fact, although the phase I study was 
not designed to establish efficacy, the slope of disease progression appeared to improve after 
surgical implantation when compared to progression rate prior to surgery, particularly in group 
C/E patients (Figure 4).83 Furthermore, in the majority of patients, GST, HHD, and electrical 
impedance myography outcomes at 9, 12 and 15 months were improved when compared to pre-
surgical baselines.83 These results generated a great deal of excitement and allowed the transition 
to a Phase IIa trial. 
 
A Phase IIa Clinical Trial 
Given these encouraging results of the Phase I safety trial, the FDA approved the Phase 
IIa trial, “A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord 
Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis” 
(NCT01730716). This trial was designed to assess the maximum tolerated dose of cells, 
measuring the same clinical assessments as the Phase I trial, and treatment groups progressively 
received increasing doses of cells via intraspinal cord injections (Table 2). Subjects in Group A 
(n = 3) received 5 bilateral (10 total) cervical injections for a total of 2 million cells. Subjects in 
Groups B, C, and D (n = 3 each) then received 10 bilateral (20 total) cervical injections of 
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increasing cell doses for a total of 4, 6, and 8 million cells, respectively. Finally, subjects in 
Group E (n = 3) received 8 million cells in 10 bilateral (20 total) cervical injections, followed a 
month later by a subsequent dose of 8 million cells in 10 bilateral (20 total) lumbar spinal cord 
injections, resulting in a total of 16 million cells. A training program for participating 
Neurosurgeons on operation of the spinal injection system was implemented prior to extending 
the trial to new sites, and this standardization will be continued in future trials.  
The final surgery was performed in July 2014 and data review is ongoing; however, the 
preliminary results are promising and we are currently planning the next Phase II/III trial is in the 
early planning phase. .Aspects of trial design that are currently under discussion include 
inclusion/exclusion criteria, the possibility of inclusion of experimental disease biomarkers, need 
for immunosuppression, appropriate primary outcome measures, as well as the feasibility and 
ethics of a placebo control group. Based on experience in the Phase I and Phase IIa trials, as well 
as the theory that stem cells improve the motor neuron microenvironment, it is anticipated that 
patients with early-stage disease would likely benefit the most. Therefore, early-stage patients 
without bulbar involvement will likely be the major target population in any future efficacy 
study.  Important outcome measures include pulmonary function tests as well as assessment of 
motor strength, in addition to survival data.  
However, these outcome measures may be meaningless without a group for comparison. 
Historical controls from previous ALS trials would likely be insufficiently matched to treatment 
groups in this stem cell paradigm. In an ideal world, any measure of therapeutic efficacy should 
be compared with a placebo control group. Particularly in surgical trials, the placebo effect can 
be strong, as underscored by recent cellular therapy approaches for Parkinson’s Disease.100 Here 
lies the crux of an ethical dilemma that accompanies stem cell trials: in a rapidly fatal disease 
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such as ALS, is it ethical to subject patients to the risks of a sham surgical procedure and 
immunosuppression for the sake of investigative rigor? Varying lead-in phases could be utilized, 
but, given the progressive nature of the disease, patients receiving stem cell transplants at a later 
stage will likely be a very different population than those receiving stem cells upfront. Placebo 
surgery could be an option, with increasing degrees of risk having been proposed: from a mere 
general anesthetic, to skin incision only, to removal only of spinous processes, even up to full 
injections with a vehicle control. The tension between scientific harmony and clinical 
nonmalfeasance will have to be carefully negotiated as these trials move forward.  
 
CONCLUSIONS: THE HORIZON 
The journey from the initial studies utilizing stem cells in preclinical models of ALS to 
the completion of the Phase I and Phase IIa trials has been long and storied, yet immensely 
rewarding. While we have focused on one series of trials utilizing NPCs, the potential benefits of 
cell-based therapy in ALS are being actively studied internationally. Many trials focus on 
autologous, intrathecal administration of bone marrow-, umbilical cord-, or adipose-derived 
mesenchymal stem cells, such as trials in China (NCT01494480), Poland (NCT02193893), Iran 
(NCT02116634, NCT02492516), South Korea,101 India (NCT02242071), and at the Mayo 
Clinic, USA (NCT01609283). A paradigm from Brainstorm-Cell Therapeutics modifies 
autologous mesenchymal stem cells to secrete a variety of neurotrophic factors prior to 
intramuscular and intrathecal co-implantation (NCT02017912).78 Similarly, Spanish groups have 
performed intraspinal injection of autologous mesenchymal stem cells,76 and are comparing 
intravenous, intramuscular, intraspinal, and intrathecal therapy (NCT01254539, NCT02286011, 
NCT02290886). A planned trial by Q Therapeutics Inc. utilizes the technique of intraspinal 
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injection described here for the introduction of glial-restricted neural progenitor cells 
(NCT02478450).  
Continued Moving forward, continued evaluation of these trials as well as other maturing 
trials for ALS (reviewed elsewhere)83, 85, 86, 102 should consider some basic tenets of stem cell 
therapy: 1) stem cells should be readily obtainable in numbers sufficient for clinical use, 2) cells 
should minimize the potential for tumor formation yet survive in sufficient numbers to benefit 
motor neurons, 3) the paradigm for cell delivery should balance CNS penetration and therapeutic 
potential with procedural reproducibility and safety, 4) clinical trial design should be robust with 
sufficient subjects to glean meaningful data, yet be sensitive to the varied presentation and 
course of disease, 5) trial outcomes should remain objective with measurements such as the 
ALSFRS-R and pulmonary function, and 6) subsequent analysis should include delineation of 
the survival, function, and potential mechanism of transplanted cells. Also relevant to future trial 
planning is the projected cost of this therapy. While accurate estimates cannot be provided given 
the early investigative aspect of these trials, the bulk of costs will likely be associated with the 
stem cell product, surgical and perioperative costs, as well as any ongoing immunosuppression. 
For the Phase I and IIa NPC transplantation trials, the stem cell product was provided at no cost 
by Neuralstem, Inc. Given the heterogeneity of the modern healthcare landscape, the hospital and 
procedural fees associated with intraspinal injection, post-operative hospitalization, and ongoing 
immunosuppression will vary from center to center. Certainly, the cost of the stem cells as well 
as the added surgical and medical costs associated with this procedure will need to be balanced 
with the estimated annual cost of disease, which is about $63,693 per year, per patient.1  
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These collective tenets and considerations will be heavily weighed as we enter into 
planning the next phase of our clinical trial and must certainly be considered with the continued 
translation and evaluation of other cellular therapy paradigms as well. 
In addition to the data obtained thus far in these and other stem cell clinical trials, the 
nascent ideas being nurtured in the laboratory also continue to inform the future of cell-based 
therapy for ALS. Particularly, much excitement surrounds applications harnessing the potential 
of induced pluripotent stem (iPS) cells, as the ability to de-differentiate adult fibroblasts into 
pluripotent stem cells confers a range of exciting and newly attainable possibilities. Most 
immediately, motor neurons derived by iPS technology from donated ALS patient tissue will 
allow in vitro study of disease mechanisms and high-throughput screening of potential 
therapeutics103-105. Furthermore, healthy individuals, and even ALS patients themselves, now 
become potential donors of stem cells that could be used in the study and treatment of ALS.106, 
107 At this time, although iPS cells would negate the need for immunosuppression, the logistics 
and cost of dedifferentiating fibroblasts, expanding a stem cell population, and differentiation 
prior to reimplantation (to prevent teratoma formation) within a time window prior to ALS 
progression is still prohibitive and at times inconsistent. However, as this and other technologies 
mature, iPS-based therapy may become a reality in the near future. Thus, in the stem cell era, 
simultaneous progress in both clinical and laboratory settings are advancing the field by 
providing patients with a therapy that may truly modify the course of disease while also gaining 
insight into the mechanisms by which stem cells provide therapeutic benefit, respectively. With 
this cycle between the laboratory and the clinic ongoing, stem cell therapy holds promise not 
only in ALS, but indeed can be implemented in a breadth of other neurologic conditions for 
which we can hold an immense degree of optimism. 
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Figure 1: Spinal cord injection system for intraspinal stem cell transplantation. (A) 
Platform consists of two bridge rails (blue) and is anchored to the spine. Gondola (green) travels 
in a cranial-caudal dimension and compensates for slight movements in the platform application. 
Mechanical Z drive (orange) allows precise raising and lowering of a floating cannula. (B) 
Cannula tip is positioned 1 mm medial to dorsal root entry zone. (C) Needle penetrates into 
spinal cord ~4 mm from pial surface. (D) Once needle tip is at the target, metal outer sleeve is 
pulled up, allowing flexible tubing to accommodate cardiorespiratory pulsations of spinal cord. 
Reproduced with permission from Boulis et al., Nat Rev Neurosci, 2011.84 
Figure 2. Donor NPC localization and characterization using XY chromosome FISH and 
IHC, respectively, in a female ALS patient. H&E staining shows nests of cells in the female 
spinal cord (A) (circle). High-power image corresponding to the nest of cells outlined in (A) is 
shown in (B). Sections stained with GFAP show lack of labeling of in nest of cells (C). FISH 
labeling shows numerous X (red) Y (green)–positive donor cells counterstained with DAPI 
(blue) (D). Asterisks show XX–positive recipient cells in the surrounding regions. Inset image 
from (D) is shown in (E). Donor NPCs are positive for XY (solid arrow). H&E labeling of NPCs 
graft (arrow) (F) label with SOX2 and (G) and NeuN (H). Scale bars: 1 mm (A), 50 µm (B–D), 
10 µm (E), 100 µm (F–H). NPC, neural progenitor cell; FISH, fluorescence in situ hybridization; 
IHC, immunohistochemistry; ALS, amyotrophic lateral sclerosis; GFAP, glial fibrillary acidic 
protein. Reproduced with permission from Tadesse et al, Ann Clin Transl Neurol, 2014.99 
Figure 3: Identification of donor DNA in ALS spinal cord. Schematic showing presence of 
donor genomic DNA from spinal cord autopsy samples in six patients (1–6) as determined by 
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quantitative PCR. The numbers adjacent to each schematic cord represent the percentage of 
donor DNA in that tissue homogenate. Human NPCs were unilaterally injected in the lumbar 
spinal cord in Patients 1, 4, and 5, bilateral lumbar in Patients 2 and 3, and unilateral cervical in 
Patient 6. The black bar identifies the region containing the highest percentage of donor DNA, 
ranging from 0.67% to 5.4%. ALS, amyotrophic lateral sclerosis; HSSCs, human spinal cord–
derived stem cells; NPC, neural progenitor cell; PCR, polymerase chain reaction. Reproduced 
with permission from Tadesse et al, Ann Clin Transl Neurol, 2014.99 
Figure 4: Analysis of potential windows of NPC biological activity in Subjects 10 to 12. 
Postsurgery data points for Group E subjects were divided into a series of 9-month windows 
beginning each month post implantation, and slopes were calculated across each window using 
ALSFRS-R and compared to presurgical windows. (A) The top panel demonstrates ALSFRS-R 
scores for Group E subjects during the presurgical period (green) and representative ranges 
associated with the various sliding postsurgical 9-month windows (dark blue). The bottom panel 
demonstrates the slopes obtained for each sliding window, with the x-axis corresponding to the 
first month for each 9-month window. The first plotted slope for each subject corresponds to 
their presurgical progression rate. Slope values higher than the presurgical slope at baseline 
represent improved or attenuated progression rates during the designated window. Note that the 
starting month of the final sliding window for each patient coincides with the dates of the second 
surgery, which occur at 17.5, 19, and 16.6 months after the initial Cohort C surgery (time 0) for 
Subjects 10, 11, and 12, respectively. (B) The presurgical slope and postsurgical slopes 
associated with the window correlating to the peak benefit windows for both the lumbar and 
cervical postsurgery time frames are summarized. ALSFRS-R, Amyotrophic Lateral Sclerosis 
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Functional Rating Scale-Revised Reproduced with permission from Feldman et al, Ann Neurol, 
2014.83 
  
Page 33 of 39
John Wiley & Sons
Annals of Neurology





















Lumbar cord 5 x 105 
A2 3 
10 total 
(5 per side) 




Lumbar cord 5 x 105 




(5 per side lumbar) 
 
(5 unilateral cervical 




Cervical cord after 
observation period 
1 x 106 
 
 
5 x 105 after 
observation period 
 




Number of injections Target Final cell dose 
A 3 10 total (5 per side) Cervical cord 2 x 10
6 
B 3 20 total (10 per side) Cervical cord 4 x 10
6 
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C 3 20 total (10 per side) Cervical cord 6 x 10
6 
D 3 20 total (10 per side) Cervical cord 8 x 10
6 
E 3 
20 total (10 per side) 
for each target, staged. 
Cervical cord, followed 
by lumbar cord 
16 x 106 
Page 35 of 39
John Wiley & Sons
Annals of Neurology













Figure 1. Spinal cord injection system for intraspinal stem cell transplantation. (A) Platform consists of two 
bridge rails (blue) and is anchored to the spine. Gondola (green) travels in a cranial-caudal dimension and 
compensates for slight movements in the platform application. Mechanical Z drive (orange) allows precise 
raising and lowering of a floating cannula. (B) Cannula tip is positioned 1 mm medial to dorsal root entry 
zone. (C) Needle penetrates into spinal cord ~4 mm from pial surface. (D) Once needle tip is at the target, 
metal outer sleeve is pulled up, allowing flexible tubing to accommodate cardiorespiratory pulsations of 
spinal cord. Reproduced with permission from Boulis et al., Nat Rev Neurosci, 2011.  
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Figure 2. Donor NPC localization and characterization using XY chromosome FISH and IHC, respectively, in a 
female ALS patient. H&E staining shows nests of cells in the female spinal cord (A) (circle). High-power 
image corresponding to the nest of cells outlined in (A) is shown in (B). Sections stained with GFAP show 
lack of labeling of in nest of cells (C). FISH labeling shows numerous X (red) Y (green)–positive donor cells 
counterstained with DAPI (blue) (D). Asterisks show XX–positive recipient cells in the surrounding regions. 
Inset image from (D) is shown in (E). Donor NPCs are positive for XY (solid arrow). H&E labeling of NPCs 
graft (arrow) (F) label with SOX2 and (G) and NeuN (H). Scale bars: 1 mm (A), 50 µm (B–D), 10 µm (E), 
100 µm (F–H). NPC, neural progenitor cell; FISH, fluorescence in situ hybridization; IHC, 
immunohistochemistry; ALS, amyotrophic lateral sclerosis; GFAP, glial fibrillary acidic protein. Reproduced 
with permission from Tadesse et al, Ann Clin Transl Neurol, 2014.  
728x932mm (72 x 72 DPI)  
 
 
Page 37 of 39
John Wiley & Sons
Annals of Neurology













Figure 3. Identification of donor DNA in ALS spinal cord. Schematic showing presence of donor genomic DNA 
from spinal cord autopsy samples in six patients (1–6) as determined by quantitative PCR. The numbers 
adjacent to each schematic cord represent the percentage of donor DNA in that tissue homogenate. Human 
NPCs were unilaterally injected in the lumbar spinal cord in Patients 1, 4, and 5, bilateral lumbar in Patients 
2 and 3, and unilateral cervical in Patient 6. The black bar identifies the region containing the highest 
percentage of donor DNA, ranging from 0.67% to 5.4%. ALS, amyotrophic lateral sclerosis; HSSCs, human 
spinal cord–derived stem cells; NPC, neural progenitor cell; PCR, polymerase chain reaction. Reproduced 
with permission from Tadesse et al, Ann Clin Transl Neurol, 2014.  
731x238mm (72 x 72 DPI)  
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Figure 4. Analysis of potential windows of NPC biological activity in Subjects 10 to 12. Postsurgery data 
points for Group E subjects were divided into a series of 9-month windows beginning each month post 
implantation, and slopes were calculated across each window using ALSFRS-R and compared to presurgical 
windows. (A) The top panel demonstrates ALSFRS-R scores for Group E subjects during the presurgical 
period (green) and representative ranges associated with the various sliding postsurgical 9-month windows 
(dark blue). The bottom panel demonstrates the slopes obtained for each sliding window, with the x-axis 
corresponding to the first month for each 9-month window. The first plotted slope for each subject 
corresponds to their presurgical progression rate. Slope values higher than the presurgical slope at baseline 
represent improved or attenuated progression rates during the designated window. Note that the starting 
month of the final sliding window for each patient coincides with the dates of the second surgery, which 
occur at 17.5, 19, and 16.6 months after the initial Cohort C surgery (time 0) for Subjects 10, 11, and 12, 
respectively. (B) The presurgical slope and postsurgical slopes associated with the window correlating to the 
peak benefit windows for both the lumbar and cervical postsurgery time frames are summarized. ALSFRS-R, 
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. Reproduced with permission from Feldman et 
al, Ann Neurol, 2014.  
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